BIRC3 and glioblastoma: Because we clearly demonstrated the clinical relevance of ML-IAP expression in GBM, we chose in this study to analyze the effect of the monovalent SMAC mimetic GDC-0152 that is described to antagonize not only cIAP1, cIAP2, XIAP and also ML-IAP.